02/08/2026 AstraZeneca and Bristol Myers Squibb Explore $400B Mega-Merger AstraZeneca and Bristol Myers Squibb Explore $400B Mega-Merger (Ref) AstraZeneca and Bristol Myers Squibb are engaged in discussions over a potential $400 billion merger, which would rank among the largest corporate deals in history Strategic Context: Bristol Myers has pursued aggressive acquisitions in the past, notably Medarex, which expanded its oncology pipeline AstraZeneca’s valuation has surged un

25/03/2026 Corcept's relacorilant + nab-paclitaxel received FDA approval for platinum-resistant Ovarian Cancer TRIANA Biomedicines' TRI-611 received the FDA fast track designation for ALK+ NSCLC In a $6.7B deal, Merck & Co acquired Terns Pharmaceuticals to expand its hematology pipeline Corcept's relacorilant + nab-paclitaxel received FDA approval for platinum-resistant Ovarian Cancer (Ref) The US FDA granted approval to Corcept Therapeutics Incorporated's Lifyorli (relacori